JPM vs NXP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
NXP exhibits severe valuation misalignment, trading at $14.16 despite a Graham Number of $6.95 and an Intrinsic Value of $1.05. While the Piotroski F-Score of 5/9 indicates stable financial health, this is overshadowed by a catastrophic payout ratio of 418%, signaling an unsustainable dividend. Negative earnings growth (-11.2% YoY) combined with an astronomical P/E ratio of 94.40 suggests the asset is significantly overpriced relative to its fundamental earning power. The technical trend is completely bearish (0/100), reinforcing a negative outlook.
Compare Another Pair
Related Comparisons
JPM vs NXP: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Nuveen Select Tax-Free Income Portfolio (NXP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.